Obinutuzumab in chronic lymphocytic leukemia.

Abstract

Obinutuzumab is the second next-generation monoclonal anti-CD20 antibody (after ofatumumab) to enter clinical practice in chronic lymphocytic leukemia. Its superiority in association with chlorambucil as compared with chlorambucil alone has led to its approval as a first-line treatment for chronic lymphocytic leukemia, for patients who are not candidates for a more intensive treatment.

• Authors: Jehan Dupuis
• Journal: Future oncology (London, England) (Future Oncol) Vol. 11 Issue 18 Pg. 2503-13 (Sep 2015) ISSN: 1744-8301 [Electronic] England
• PMID: 26285615 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents
• obinutuzumab

Topics

• Antibodies, Monoclonal, Humanized (chemistry, pharmacology, therapeutic use)
• Antineoplastic Agents (chemistry, pharmacology, therapeutic use)
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Clinical Trials, Phase III as Topic
• Humans
• Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy, genetics, metabolism, mortality)
• Pharmacogenetics
• Product Surveillance, Postmarketing
• Treatment Outcome